Cargando…

Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals

OBJECTIVES: Thanks to its long half-life, dalbavancin qualifies as an optimal drug for saving costs. We aimed to assess the cost and effectiveness of dalbavancin versus the standard of care (SoC). PATIENTS AND METHODS: We conducted a multicentre retrospective study, including all hospitalized or out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Francesca, Mazzitelli, Maria, Silvola, Sofia, Raumer, Francesca, Restelli, Umberto, Croce, Davide, Marchetti, Giulia, Cattelan, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116602/ https://www.ncbi.nlm.nih.gov/pubmed/37090914 http://dx.doi.org/10.1093/jacamr/dlad044

Ejemplares similares

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

To Add or Not to Add: Would the Addition of Dalbavancin to Formulary Decrease Admissions for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)?
por: Freshwater, Dustin, et al.
Publicado: (2017)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

1385. Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
por: Lovecchio, Frank, et al.
Publicado: (2022)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature Review
por: Silvola, Sofia, et al.
Publicado: (2023)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
por: Brescini, Lucia, et al.
Publicado: (2021)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Patient Preferences in the Emergency Department (ED) Before Treatment for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2017)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)
por: Restelli, Umberto, et al.
Publicado: (2015)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
por: Bradley, John S, et al.
Publicado: (2019)

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients
por: Pizzuti, Adam G., et al.
Publicado: (2020)

Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital
por: Loo, Li Wen, et al.
Publicado: (2015)

Variability in Emergency Medicine (EM) Provider Decisions on Hospital Admission and Antibiotic (ABX) Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2017)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

1977. Comparative Effectiveness of Linezolid vs. Trimethoprim–Sulfamethoxazole for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) at a Veterans Affairs Hospital
por: Tan, Xing, et al.
Publicado: (2018)

Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
por: Restelli, Umberto, et al.
Publicado: (2015)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

Analysis of the correlation between mortality in nursing homes and among elderly population in Italy during the first phase of COVID-19 pandemic
por: SEBASTIANO, ANTONIO, et al.
Publicado: (2022)

Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
por: Restelli, Umberto, et al.
Publicado: (2020)

289. International Validation of a Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Assessment Tool for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Zasowski, Evan J, et al.
Publicado: (2018)

2289. Bacterial Causes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Intravenous Drug Use (IVDU): Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population
por: Murray, E Yancey, et al.
Publicado: (2020)

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
por: McCarthy, Matthew W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_llijcpgatu95742obtdjro7m9d